![]() |
市場調査レポート
商品コード
1379125
新生児スクリーニング市場レポート:製品、技術、検査タイプ、地域別、2023-2028年Newborn Screening Market Report by Product, Technology, Test Type, and Region 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
新生児スクリーニング市場レポート:製品、技術、検査タイプ、地域別、2023-2028年 |
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2~3営業日
|
世界の新生児スクリーニング市場規模は、2022年に9億5,600万米ドルに達しました。今後、IMARC Groupは、市場は2028年までに14億6,700万米ドルに達し、2022年から2028年の間に7.4%の成長率(CAGR)を示すと予測しています。様々な重篤な疾患の早期発見に対する意識の高まり、有利な政府の取り組み、より正確な結果と効率的な疾患検出のための医療技術の革新は、市場を推進する主な要因の一部です。
新生児スクリーニングは、出生直後の乳児の特定の健康状態を特定するための重要な公衆衛生アプローチです。赤ちゃんのかかとから数滴の血液を採取して実施されます。これにより、症状が現れる前であっても、潜在的に深刻な状態を早期に発見することができます。先天性疾患、代謝異常、遺伝性疾患など、幅広い疾患の評価に役立ちます。これに加えて、ヘルスケア専門家は、これらの状態の影響を予防または最小化することによって、タイムリーな介入や治療を開始することができます。
現在、子供たちのQOL向上に対する需要の高まりが市場の成長を支えています。これに加えて、世界の出生率の上昇とともに、遺伝性疾患や代謝性疾患の有病率の増加が市場の成長を強化しています。さらに、治療結果の改善とヘルスケアコストの削減を提供するスクリーニング検査に対する需要の高まりが、市場にプラスの影響を与えています。これとは別に、新生児スクリーニングの効率を高めるためのデータ管理と分析ツールの統合が進んでいることは、業界の投資家に有利な成長機会を提供しています。さらに、親たちの間で全人的な幸福と予防ヘルスケア対策への関心が高まっていることも、市場の成長を後押ししています。これに伴い、ヘルスケア分野での自動化とデジタル化の普及が進み、市場の成長を促進しています。
病気の早期発見に対する意識の高まり
病気の早期発見が非常に重要であるという保護者の意識の高まりが、市場の成長に寄与しています。これに伴い、疾患の早期発見は、タイムリーな介入、治療結果の改善、子供の生活の質の向上に役立ちます。また、個人の健康と幸福を守ることにも役立ちます。これとは別に、潜在的な合併症を回避し、ヘルスケアシステムの負担を軽減し、全体的な生活の質を向上させることができます。さらに、病気の早期発見を提供する高度なスクリーニング技術やヘルスケアサービスに対する需要の高まりが、市場の成長を後押ししています。
政府の積極的な取り組み
各国の政府機関は、世界中の健康状態を予防・管理するために新生児スクリーニングの導入を奨励しており、これは市場の見通しに好影響を与えています。加えて、政府は新生児スクリーニングを義務化するプログラムを実施しており、これによりこれらのサービスがより多くの人々にとって利用しやすくなっています。また、多くの場合、疾患の包括的なパネルをカバーし、幅広い潜在的な健康問題に効率的に対処できるようにする取り組みも行っています。さらに、医療従事者に知識を広め、人々に指針を提供するための教育キャンペーンも行っています。
その結果、こうした取り組みは、世界中で病気の早期発見の利点について大衆の意識を喚起するのに役立っています。
医療技術の革新
さまざまなメーカーが、新生児スクリーニング法を強化するために医療技術を急速に進歩させています。さらに、タンデム質量分析(MS)やデオキシリボ核酸(DNA)ベースの検査などの革新的な技術は、病気検出の精度と効率を高めるのに役立っています。これらの技術は、より広範な疾患の同時スクリーニングを可能にし、診断能力を高め、まれな疾患であっても早期発見を可能にします。これとは別に、このようなスクリーニング技術の出現は、ヘルスケアプロバイダーがこれらのサービスを採用し、提供することを奨励しています。さらに、技術の進歩は侵襲性を最小限に抑え、回復時間を短縮し、患者の快適性を向上させると同時に、医療介入のスピードを向上させる。
The global newborn screening market size reached US$ 956 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,467 Million by 2028, exhibiting a growth rate (CAGR) of 7.4% during 2022-2028. The growing awareness about early disease detection of various severe diseases, favorable government initiatives, and innovations in medical technology for more accurate outcomes and efficiency of disease detection are some of the major factors propelling the market.
Newborn screening is a vital public health approach that is designed to identify certain health conditions in infants shortly after birth. It is performed through a few drops of blood taken from the heel of the baby. It allows for the early detection of potentially serious conditions, even before symptoms appear. It assists in assessing a wide range of congenital disorders, metabolic irregularities, and genetic diseases. Besides this, it enables healthcare professionals to initiate timely interventions and treatments by preventing or minimizing the impact of these conditions.
At present, the rising demand for enhanced quality of life among children is supporting the growth of the market. Besides this, the increasing prevalence of genetic and metabolic disorders, along with rising birth rates across the globe, is strengthening the growth of the market. Additionally, the growing demand for screening tests that offer improved outcomes and reduced healthcare costs is positively influencing the market. Apart from this, the increasing integration of data management and analysis tools to enhance the efficiency of newborn screening is offering lucrative growth opportunities to industry investors. Furthermore, the rising focus on holistic well-being and preventive healthcare measures among parents is bolstering the growth of the market. In line with this, the increasing popularity of automation and digitalization in the healthcare sector is propelling the growth of the market.
Rising awareness about early disease detection
The rising awareness among parents about the critical importance of early disease detection is contributing to the growth of the market. In line with this, early disease detection assists in offering timely intervention, improved treatment outcomes, and enhanced quality of life for the child. It also aids in safeguarding individual health and well-being. Apart from this, it can avoid potential complications, reduce the burden on healthcare systems, and improve the overall quality of life. Furthermore, the increasing demand for advanced screening technologies and healthcare services that offer early disease detection is bolstering the growth of the market.
Favorable government initiatives
Governing agencies of various countries are encouraging the adoption of newborn screening to prevent and manage health conditions around the world, which is offering a positive market outlook. In addition, they are implementing mandatory newborn screening programs, which makes these services more accessible to a larger population. They are also taking initiatives that often cover a comprehensive panel of disorders and ensure that a wide range of potential health issues are addressed efficiently. Furthermore, they are organizing educational campaigns to spread knowledge among healthcare providers to provide guidance to people.
As a result, these initiatives benefit in generating awareness among the masses about the benefits of early detection of diseases across the globe.
Innovations in medical technology
Various manufacturers are rapidly advancing their medical technologies to enhance newborn screening methods. In addition, innovative techniques, such as tandem mass spectrometry (MS) and deoxyribonucleic acid (DNA)-based testing, assist in increasing the accuracy and efficiency of disease detection. These technologies enable the simultaneous screening of a broader range of disorders, enhance diagnostic capabilities, and allow for early identification of even rare conditions. Apart from this, the emergence of these screening technologies encourages healthcare providers to adopt and offer these services. Furthermore, advancements in technologies minimize invasiveness, reduce recovery times, and improve patient comfort while enhancing the speed of medical interventions.
IMARC Group provides an analysis of the key trends in each segment of the global newborn screening market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on product, technology and test type.
Instruments
Reagents
Instruments represents the largest market segment
The report has provided a detailed breakup and analysis of the market based on the product. This includes instruments and reagents. According to the report, instruments represented the largest segment. Instruments play an important role in the screening process by providing the necessary tools for sample collection, analysis, and result interpretation. These devices comprise a diverse range of technologies, such as mass spectrometry systems, deoxyribonucleic acid (DNA) analyzers, and automated screening platforms. These instruments are designed to ensure accuracy, efficiency, and reproducibility in the screening procedures. They enable healthcare professionals to process a high volume of samples with precision and facilitate the early detection of various disorders. Furthermore, the rising demand for reliable and user-friendly instruments is supporting the growth of the market.
Tandem Mass Spectrometry
Pulse Oximetry
Enzyme Based Assay
DNA Assay
Electrophoresis
Others
Tandem mass spectrometry accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the technology. This includes tandem mass spectrometry, pulse oximetry, enzyme based assay, DNA assay, electrophoresis, and others. According to the report, tandem mass spectrometry represented the largest segment. Tandem mass spectrometry is an analytical technique that is employed in newborn screening to identify a range of metabolic disorders. It involves two stages of mass spectrometry, where ions are fragmented and analyzed for precise identification of compounds. Apart from this, it offers enhanced accuracy and speed and can detect rare disorders. In line with this, technological advancements in the medical field enhance the sensitivity and specificity of tandem mass spectrometry that offers improved health outcomes for infants worldwide.
Dry Blood Spot Test
CCHD
Hearing Screen
Dry blood spot holds the biggest market share
The report has provided a detailed breakup and analysis of the market based on the test type. This includes dry blood spot test, CCHD, and hearing screen. According to the report, dry blood spot test represented the largest segment. A dry blood spot test is a non-invasive and widely utilized screening technique that involves collecting a small amount of blood from the heel of a newborn onto a special filter paper. This dried blood sample is then analyzed for the presence of specific markers associated with various disorders. Apart from this, it enables early detection of conditions, such as congenital hypothyroidism and sickle cell disease. Moreover, the rising preference for dry blood spot tests in many newborn screening programs, as they offer the convenience of sample collection, ease of transportation, and the ability to simultaneously screen for multiple conditions, is bolstering the growth of the market.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest newborn screening market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share due to the presence of advanced healthcare infrastructure. In addition, the rising awareness about the long-term benefits of newborn screening among individuals is strengthening the growth of the market in the region. Apart from this, favorable government initiatives and regulations are offering a positive market outlook. In line with this, the increasing focus on preventive healthcare is supporting the growth of the market in the North America region.
Various manufacturers are investing in research and development (R&D) activities to provide innovative screening technologies and methods. This includes refining existing techniques like tandem mass spectrometry and exploring new approaches to broaden the scope of conditions detected. In addition, companies are providing a more comprehensive screening service by adding more conditions to their test panels. Apart from this, key players are focusing on developing automated systems that streamline the screening process, from sample collection to result interpretation, to enhance efficiency, reduce human error, and allow for faster turnaround times. Furthermore, companies are focusing on data management solutions to ensure accurate record-keeping, easy access to results, and data integration with electronic health records.
Agilent Technologies Inc.
Baebies Inc.
Bio-RAD Laboratories Inc.
Chromsystems Instruments & Chemicals GmbH
Danaher Corporation
Masimo Corporation
Medtronic plc
Natus Medical Incorporated
Perkinelmer Inc.
RECIPE Chemicals + Instruments GmbH
Thermo Fisher Scientific Inc.
Trivitron Healthcare
Waters Corporation
In August 2022, Trivitron Healthcare inaugurated its centre-of-excellence with state-of-the-art research and development (R&D) and manufacturing facilities at AMTZ Campus, Vishakhapatnam, India for metabolomics, genomics, newborn screening, and molecular diagnostics.
In November 2020, Natus Medical Inc., a leading provider of medical device solutions, acquired German healthcare equipment company Babybe GmbH and its patented remote mother to baby communication technology. The Babybe technology has been added to Natus's market leading Newborn Care portfolio of products.
In November 2022, PerkinElmer Inc. announced that the U.S. Food and Drug Administration (FDA) has authorized the marketing of the EONIS™ SCID-SMA assay kit for in vitro diagnostic (IVD) use by certified laboratories for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.